Genpharmasec Ltd
Incorporated in 1992, Generic Pharmasec
Ltd deals in pharmaceutical activities /services and trades in equity shares[1]
- Market Cap ₹ 51.5 Cr.
- Current Price ₹ 0.93
- High / Low ₹ 2.38 / 0.75
- Stock P/E 17.7
- Book Value ₹ 1.24
- Dividend Yield 0.00 %
- ROCE 5.43 %
- ROE 3.77 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 0.63 times its book value
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 30.0%
- Company has a low return on equity of 3.01% over last 3 years.
- Earnings include an other income of Rs.4.31 Cr.
- Debtor days have increased from 113 to 148 days.
- Promoter holding has decreased over last 3 years: -30.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.02 | 0.00 | 0.48 | 0.08 | 0.38 | 16.50 | 21.31 | 27.32 | 25.52 | 30.41 | 32.93 | 93.24 | |
| 0.04 | 0.40 | 0.11 | 0.54 | 0.11 | 0.46 | 15.85 | 20.12 | 27.84 | 25.26 | 30.26 | 32.49 | 93.40 | |
| Operating Profit | -0.04 | -0.38 | -0.11 | -0.06 | -0.03 | -0.08 | 0.65 | 1.19 | -0.52 | 0.26 | 0.15 | 0.44 | -0.16 |
| OPM % | -1,900.00% | -12.50% | -37.50% | -21.05% | 3.94% | 5.58% | -1.90% | 1.02% | 0.49% | 1.34% | -0.17% | ||
| 0.06 | 0.40 | 0.21 | 0.07 | 0.09 | 0.37 | 0.56 | 0.33 | 0.09 | 0.10 | 0.72 | 3.43 | 4.31 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.39 | 0.29 | 0.41 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.13 | 0.19 |
| Profit before tax | 0.02 | 0.02 | 0.10 | 0.01 | 0.06 | 0.29 | 1.21 | 1.51 | -0.44 | 0.28 | 0.46 | 3.45 | 3.55 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 33.33% | 20.69% | 16.53% | 16.56% | -52.27% | -300.00% | 91.30% | 28.41% | |
| 0.02 | 0.02 | 0.10 | 0.02 | 0.05 | 0.23 | 1.01 | 1.26 | -0.21 | 1.12 | 0.05 | 2.47 | 2.91 | |
| EPS in Rs | 0.00 | 0.00 | 0.01 | 0.03 | 0.07 | 0.01 | 0.02 | 0.02 | -0.00 | 0.02 | 0.00 | 0.04 | 0.05 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 110% |
| 5 Years: | 15% |
| 3 Years: | 6% |
| TTM: | 215% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 62% |
| 5 Years: | 20% |
| 3 Years: | 140% |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | -31% |
| 3 Years: | -25% |
| 1 Year: | -59% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 3% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.52 | 6.52 | 6.52 | 0.33 | 0.33 | 21.69 | 21.69 | 27.69 | 27.69 | 27.69 | 55.37 | 55.37 | 55.37 |
| Reserves | -7.56 | -7.54 | -7.44 | -1.23 | -1.19 | -0.07 | -2.65 | -7.02 | -12.32 | -12.36 | 9.20 | 11.18 | 13.51 |
| 1.06 | 1.07 | 0.98 | 1.05 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 3.08 | 3.21 | 3.43 | 3.26 | |
| 0.19 | 0.00 | 0.00 | 0.44 | 0.02 | 0.01 | 5.71 | 7.15 | 6.28 | 1.46 | 2.70 | 9.11 | 40.83 | |
| Total Liabilities | 0.21 | 0.05 | 0.06 | 0.59 | 0.15 | 21.63 | 24.75 | 27.82 | 21.65 | 19.87 | 70.48 | 79.09 | 112.97 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.10 | 0.10 | 0.10 | 0.36 | 0.29 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.53 | 5.76 | 7.81 | 2.45 | 0.95 | 19.52 | 19.94 | 25.63 |
| 0.21 | 0.05 | 0.06 | 0.59 | 0.15 | 14.10 | 18.94 | 19.96 | 19.10 | 18.82 | 50.86 | 58.79 | 87.05 | |
| Total Assets | 0.21 | 0.05 | 0.06 | 0.59 | 0.15 | 21.63 | 24.75 | 27.82 | 21.65 | 19.87 | 70.48 | 79.09 | 112.97 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.03 | 0.10 | -0.05 | 0.14 | -6.40 | 1.39 | -2.13 | -2.34 | -3.06 | -2.27 | 3.45 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.42 | -4.01 | -1.41 | 0.42 | 0.36 | -29.03 | -16.45 | |
| -0.03 | 0.01 | -0.10 | 0.07 | -0.06 | 21.87 | 0.00 | 4.50 | 0.00 | 3.08 | 47.89 | -0.44 | |
| Net Cash Flow | -0.02 | 0.04 | 0.00 | 0.02 | 0.08 | 5.04 | -2.62 | 0.96 | -1.93 | 0.39 | 16.59 | -13.44 |
| Free Cash Flow | 0.01 | 0.03 | 0.10 | -0.05 | 0.14 | -6.40 | 1.34 | -2.14 | -2.42 | -3.08 | -2.29 | 3.44 |
| CFO/OP | -25% | -8% | -91% | 83% | -433% | 7,925% | 223% | -162% | 400% | -1,277% | -1,487% | 793% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 387.81 | 0.00 | 38.42 | 155.51 | 128.80 | 86.17 | 81.67 | 109.22 | 148.42 | ||
| Inventory Days | 0.00 | 0.00 | 82.87 | 146.00 | 135.91 | 151.06 | 133.17 | 101.96 | ||||
| Days Payable | 132.68 | 135.35 | 85.48 | 21.38 | 35.85 | 102.59 | ||||||
| Cash Conversion Cycle | 0.00 | 387.81 | 0.00 | 38.42 | 105.70 | 139.45 | 136.61 | 211.34 | 206.54 | 147.79 | ||
| Working Capital Days | 0.00 | 45.62 | -136.88 | 941.32 | 117.24 | 144.39 | 149.77 | 199.09 | 204.88 | 148.86 | ||
| ROCE % | 66.67% | 57.14% | -36.36% | 9.52% | 42.86% | 2.48% | 5.95% | 7.61% | -2.44% | 2.01% | 1.97% | 5.43% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Permanent Employees Number |
|
||||||||||
| Import Volume - i-STAT Analyzers Units |
|||||||||||
| Import Volume - i-STAT Cartridges Units |
|||||||||||
| Import Volume - Simulators Units |
|||||||||||
| DHPL Injectables Manufacturing Capacity Utilization Target % |
|||||||||||
Documents
Announcements
-
Closure of Trading Window
26 Mar - Trading window closed Apr 1, 2026 until 48 hours post audited results for year ended Mar 31, 2026.
-
Outcome Of Separate Meeting Of Independent Directors Of The Company.
24 Mar - Independent Directors met 24-Mar-2026; reviewed board and chair performance and information flow; meeting 11:00–11:30.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Feb - Newspaper Publication of Unaudited Financial Result for the quarter ended December 31, 2025.
-
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 31St December, 2025.
9 Feb - Rights issue Rs.4,845.05 lakh (allotment 21 Feb 2024); no deviation in proceeds utilization.
- Unaudited Standalone & Consolidated Financial Result Of The Company For The Quarter Ended December 31, 2025. 9 Feb
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
GPL started as a manufacturer and trader of organic and inorganic chemicals, dyes and pigments and then shifted its business activities to buying, selling and distribution of pharmaceutical, medicinal and medicated preparations and also decided to deal in securities market. Currently, company is dealing in medical and diagnostics devices